Edition:
United States

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

96.34GBp
14 Dec 2018
Change (% chg)

7.36 (+8.27%)
Prev Close
88.98
Open
88.88
Day's High
99.92
Day's Low
87.72
Volume
5,450,981
Avg. Vol
3,471,504
52-wk High
504.60
52-wk Low
75.48

Latest Key Developments (Source: Significant Developments)

Indivior Says Perseris Now Available In U.S. For Treatment Of Schizophrenia In Adults
Monday, 19 Nov 2018 08:02am EST 

Nov 19 (Reuters) - Indivior PLC ::INDIVIOR PLC - PERSERIS(TM) AVAILABILITY.INDIVIOR - FIRST ONCE-MONTHLY RISPERIDONE-CONTAINING SUBCUTANEOUS LONG-ACTING INJECTABLE, AVAILABLE IN U.S. FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS.INDIVIOR PLC - PERSERIS IS APPROVED BY U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS.INDIVIOR PLC - ANTICIPATING, AND PREPARING FOR, A FULL PROMOTIONAL LAUNCH BY SALESFORCE FOR PERSERIS IN FEBRUARY 2019.INDIVIOR- LAUNCH FOR PERSERIS CONTINGENT ON U.S. COURT UPHOLDING PRELIMINARY INJUNCTION ON GENERIC BUPRENORPHINE, NALOXONE FILM AGAINST DR REDDY'S.  Full Article

Indivior Posts Rise in Qtrly Earnings, Affirms FY Guidance
Thursday, 1 Nov 2018 07:01am EDT 

Nov 1 (Reuters) - Indivior Plc ::3RD QUARTER RESULTS.ON TRACK TO ACHIEVE FY 2018 REVISED GUIDANCE OF NET REVENUE IN RANGE OF $990-$1,020 MLN.QTRLY REVENUE $245 MILLION VERSUS $275 MILLION REPORTED LAST YEAR.ON TRACK TO ACHIEVE FY 2018 REVISED GUIDANCE OF ADJUSTED NET INCOME IN RANGE OF $230-$255 MLN.INDIVIOR PLC QTRLY NET INCOME $89 MILLION VERSUS $50 MILLION REPORTED LAST YEAR.INDIVIOR PLC QTRLY ADJUSTED NET INCOME $58 MILLION VERSUS $47 MILLION REPORTED LAST YEAR.SUBOXONE FILM MARKET SHARE AVERAGED 54 PCT YTD 2018 (YTD 2017: 58 PCT), EXITING Q3 2018 AT 52 PCT.CONFIRMS THAT FY 2018 SUBLOCADE NET REVENUES ARE EXPECTED IN RANGE OF $8 MLN TO $10 MLN.MAKING GOOD PROGRESS AGAINST ITS PREVIOUSLY-ANNOUNCED COST SAVINGS INITIATIVE THAT TARGETS AT LEAST $55M IN PRE-TAX SAVINGS IN 2018.COST SAVINGS EXPECTED TO GENERATE ANNUAL PRE-TAX SAVINGS BETWEEN $80 MLN TO $100 MLN IN FY 2019.EXPECTS ADVERSE IMPACT OF DR. REDDY'S LABORATORIES' "AT-RISK" LAUNCH ON FY 2018 NET REVENUE TO BE BETWEEN $12 MLN AND $18 MLN.COST SAVINGS TO HELP MITIGATE AGAINST POTENTIAL IMPACTS TO CO'S PROFITABILITY FROM POTENTIAL GENERIC FILM ENTRANT IN U.S..  Full Article

Merian Global Investors Cuts Stake In Indivior To Below 5 Pct From 8.02 Pct- Filing
Wednesday, 31 Oct 2018 09:12am EDT 

Oct 31 (Reuters) - Indivior PLC ::MERIAN GLOBAL INVESTORS CUTS STAKE IN INDIVIOR PLC TO BELOW 5% FROM AN EARLIER STAKE OF 8.02%.  Full Article

Standard Life Aberdeen Affiliates Raises Stake To 10.03 Pct In Indivior
Thursday, 20 Sep 2018 10:50am EDT 

Sept 20 (Reuters) - Indivior PLC ::STANDARD LIFE ABERDEEN AFFILIATES RAISES STAKE TO 10.03 PERCENT FROM 7.09 PERCENT IN INDIVIOR PLC - FILING.  Full Article

Indivior Says ‍U.S. Court Found Alvogen Does Not Infringe Claims Of Certain U.S. Patent​s
Friday, 23 Mar 2018 03:01am EDT 

March 23 (Reuters) - Indivior Plc ::INDIVIOR RESPONDS TO COURT RULING ANDA LITIGATION.‍RESPONDS TO COURT RULING IN ANDA LITIGATION AND ANNOUNCES INTENTION TO APPEAL.INDIVIOR - ‍US DISTRICT COURT FOR DISTRICT OF DELAWARE HAS FOUND THAT ALVOGEN DOES NOT INFRINGE ASSERTED CLAIMS OF CERTAIN U.S. PATENT​S.INDIVIOR PLC <<>> - ‍BELIEVES THAT IT HAS GROUNDS TO APPEAL RULING BY DISTRICT COURT OF DELAWARE​.INDIVIOR - WILL NOT BE ABLE TO RELY ON '514, '150, AND '497 PATENTS TO PREVENT ALVOGEN FROM MANUFACTURING AND MARKETING A GENERIC FILM ALTERNATIVE IN US​​.‍FINANCIAL GUIDANCE FOR FY 2018, PROVIDED BY INDIVIOR ON FEBRUARY 15, 2018, IN ITS FY 2017 RESULTS, ASSUMED NO GENERIC FILM LAUNCH IN 2018​.‍COMPANY WILL CONTINUE TO MONITOR MARKET CONDITIONS AND WILL UPDATE ITS FINANCIAL GUIDANCE IF APPROPRIATE..INDIVIOR - WILL NOT BE ABLE TO RELY ON '514, '150, AND '497 PATENTS TO PREVENT ALVOGEN FROM MANUFACTURING AND MARKETING A GENERIC FILM ALTERNATIVE IN US​.INDIVIOR PLC <<>> - ‍IF FDA GRANTS APPROVAL TO ALVOGEN, IT WOULD BE ABLE TO MARKET A GENERIC ALTERNATIVE TO SUBOXONE® FILM IN US​.INDIVIOR - ‍EXPECT TO EXTEND MARKET LEADING POSITION IN ADDICTION DISEASE SPACE, REMAIN CONFIDENT IN ACHIEVING AT LEAST $1 BLN IN PEAK SUBLOCADE NET REVENUE​​.  Full Article

Indivior Says FY 2017 ‍Net Revenue Increased 3% On Reported Basis
Thursday, 15 Feb 2018 02:00am EST 

Feb 15 (Reuters) - Indivior Plc ::FY 2017 ‍NET REVENUE AT $1,093M (FY 2016: $1,058M) INCREASED 3% ON A REPORTED BASIS (3% AT CONSTANT EXCHANGE)​.FY 2017 ‍NET INCOME WAS $58M (FY 2016: $35M)​.FY 2017 ‍CASH BALANCE AT PERIOD END WAS $863M (FY 2016: $692M). NET CASH WAS $376M (FY 2016: $131M)​.  Full Article

Indivior Expects High Teens Effective Tax Rate For 2018​
Thursday, 1 Feb 2018 02:00am EST 

Feb 1 (Reuters) - Indivior Plc ::INDIVIOR PROVIDES UPDATE ON TAX POSITION.‍EXPECTS ITS FUTURE US AFTER-TAX INCOME TO BE POSITIVELY IMPACTED BY RECENTLY-LEGISLATED CHANGES TO US CORPORATE TAXES​.‍EXPECTS A HIGH TEENS EFFECTIVE TAX RATE FOR 2018​.‍ESTIMATED IMPACT OF THIS WILL BE A ONE-OFF NON-CASH CHARGE TO COMPANY'S AFTER-TAX INCOME OF APPROXIMATELY $15 MILLION THAT WILL IMPACT Q4.  Full Article

Addex and Indivior Sign Strategic Partnership
Wednesday, 3 Jan 2018 01:00am EST 

Jan 3 (Reuters) - ADDEX THERAPEUTICS LTD ::REG-ADDEX AND INDIVIOR SIGN STRATEGIC PARTNERSHIP TO ACCELERATE DEVELOPMENT OF GABAB PAMS AS ADDICTION TREATMENTS.UNDER TERMS OF AGREEMENT, ADDEX WILL RECEIVE $5 MILLION UPFRONT.UNDER TERMS OF AGREEMENT WILL RECEIVE $4 MILLION OF COMMITTED RESEARCH FUNDING OVER NEXT TWO YEARS.TO RECEIVE $330 MILLION OF POTENTIAL DEVELOPMENT.WILL RECEIVE REGULATORY AND COMMERCIALIZATION MILESTONES AND TIERED ROYALTIES UP TO DOUBLE-DIGIT.  Full Article

‍Indivior Says Repricing And Maturity Extension Of Term Loan Facilities
Tuesday, 19 Dec 2017 02:00am EST 

Dec 19 (Reuters) - INDIVIOR PLC ::‍INDIVIOR ANNOUNCES REPRICING AND MATURITY EXTENSION OF TERM LOAN FACILITIES AND REPLACEMENT OF CREDIT FACILITY​.‍ENTERED AMENDMENT WITH VARIOUS LENDERS TO PROVIDE REPLACEMENT TERM LOAN FACILITIES IN AN AGGREGATE PRINCIPAL AMOUNT OF APPROXIMATELY $484 MILLION​.‍NEW TERM LOAN FACILITIES REDUCE GROUP'S INTEREST COUPON TO LIBOR PLUS 4.50% FROM LIBOR PLUS 6.00 PERCENT​.  Full Article

Indivior Announces NDA Acceptance Of RBP-7000 Risperidone Monthly Depot
Tuesday, 12 Dec 2017 07:00am EST 

Dec 12 (Reuters) - Indivior Plc ::INDIVIOR ANNOUNCES NDA ACCEPTANCE OF RBP-7000 RISPERIDONE MONTHLY DEPOT.FDA HAS SET A PDUFA TARGET ACTION DATE OF JULY 28, 2018.  Full Article

Indivior wins fresh hold on Dr. Reddy's Suboxone copy

Indivior Plc has secured another hold on the launch of a generic competitor to its best-selling opioid addiction drug in the United States, the London-listed company said on Wednesday.